Green Park Pharma is a Newquay-based pharmaceutical company focused on converting established tablet medicines into stable, licensed liquid formulations that remain effective at room temperature and have long shelf lives. Its patented technology targets the 20–40% of global patients, including paediatric and dysphagic adults, who struggle with solid-dose medications. By eliminating the need for pharmacists to reconstitute powders, the firm improves dosage accuracy, medication adherence and overall convenience for caregivers and health systems such as the NHS. The company positions its products as fully licensed, patent-protected equivalents to their solid predecessors, giving it a defensible market niche. Recent funding will be channelled into scaling operations, broadening international reach and hiring ten additional staff over the next three years. Management believes these steps will accelerate market penetration and establish the platform for future product launches. Financially, the business is in a pre-Series A phase, having just secured new equity to drive growth.

Total raised

$1M

Funding rounds

1

Latest round

Series A

Latest activity

Jan 2026